Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03208387 · ClinicalTrials.gov registry record
Understanding the Late Effects of Surviving a Pediatric Brain Tumor
A clinical trial of Brain Tumor and Pediatric Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 42
- Enrollment target
- 4
- Study locations
NCT03208387 is a study of Brain Tumor and Pediatric Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03208387, a study of Brain Tumor and Pediatric Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this study is to learn about the cognitive and behavioral functioning of children being treated for cancer.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Diffusion tensor imaging (DTI)
- DIAGNOSTIC_TEST Resting state functional connectivity MRI (rs-fcMRI)
- BEHAVIORAL Wechsler Intelligence Scale for Children - 5th edition (WISC-V)
- BEHAVIORAL California Verbal Learning Test (CVLT-C)
- BEHAVIORAL Beery Test of Visual Motor Integration 6th edition
Study Locations (4)
New York
- Columbia University - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03208387
The ClinicalTrials.gov registry entry for NCT03208387 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (85% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Brain Tumor appearing as the primary indexed condition, and to 5 interventions - of which Diffusion tensor imaging (DTI) is the first listed.
NCT03208387 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT03208387 about?
NCT03208387 is a clinical study titled "Understanding the Late Effects of Surviving a Pediatric Brain Tumor". The goal of this study is to learn about the cognitive and behavioral functioning of children being treated for cancer.
What is the current status of trial NCT03208387?
This trial is currently active not recruiting. The enrollment target is 42 participants. The study started on 2017-06-28. Estimated completion is 2026-06.
What conditions does trial NCT03208387 study?
This clinical trial studies the following conditions: Brain Tumor, Pediatric Cancer, Pediatric Brain Tumor.
What interventions are being tested in trial NCT03208387?
The interventions under investigation include: Diffusion tensor imaging (DTI) (DIAGNOSTIC_TEST), Resting state functional connectivity MRI (rs-fcMRI) (DIAGNOSTIC_TEST), Wechsler Intelligence Scale for Children - 5th edition (WISC-V) (BEHAVIORAL), California Verbal Learning Test (CVLT-C) (BEHAVIORAL), Beery Test of Visual Motor Integration 6th edition (BEHAVIORAL).
Who is sponsoring clinical trial NCT03208387?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03208387 being conducted?
This trial has 4 study locations across New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.